Researchers have found that genomic risk distribution can vary widely across clinical stage groups among patients with prostate cancer. Researchers have found that genomic risk distribution can vary widely across clinical stage groups among patients with prostate cancer.
Studies presented at SUO 2023 have shed new light on risk stratification and novel treatments in prostate cancer. Studies presented at SUO 2023 have shed new light on risk stratification and novel treatments in prostate cancer.
Researchers have found that genomic risk distribution can vary widely across clinical stage groups among patients with prostate cancer. Researchers have found that genomic risk distribution can vary widely across clinical stage groups among patients with prostate cancer.